Novo Nordisk debuts new diabetes drug Xultophy in UK

8 June 2015

Danish diabetes care giant Novo Nordisk (NOV: N) said today that Xultophy(insulin degludec/liraglutide; IDegLira), the first ever treatment combining two existing treatments, long acting (basal) insulin (insulin degludec, Tresiba)and GLP-1 receptor agonist (liraglutide, Victoza)in one pen, has been launched in the UK.

Xultophy saw its first launch earlier this year in Switzerland (The Pharma Letter January 19). Novo Nordisk's fixed-dose combination (FDC) is set to become the clinical gold-standard among FDCs used to treat patients with type 2 diabetes, according to market research firm decision Resources, due to the combined actions of the highly efficacious individual components on various measures of glycemic control.

Xultophyis indicated for the treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycemic control.Adults with type 2 diabetes taking once-daily Xultophy had a significant improvement in blood sugar (measured by HbA1c).4 Additionally, Xultophywas shown to have a secondary benefit of weight loss and a low rate of hypoglycaemia (very low blood sugar), comparable to Tresiba.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK